Latest & greatest articles for ramipril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ramipril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ramipril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ramipril

1. Ramipril

Ramipril Top results for ramipril - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ramipril The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

2. [Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?]. (PubMed)

[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?]. Ramipril administered once daily is characterized by an attenuation of its pharmacological activity in the following 24 hours, whose effects on antiproteinuric activity have not yet been investigated.The antiproteinuric efficacy of Ramipril has been evaluated in a cross-over study in 20 patients with renal disease, proteinuria and hypertension (GFR50 mL / min, proteinuria <3 g / day; SBP/DBP 150 (...) /90 mmHg). Proteinuria was measured over 24 hours on three consecutive urine collections (morning, afternoon and night) in the absence of antiproteinuric drugs and after ten days of treatment with single morning administration of Ramipril 2.5 mg or Ramipril 10 mg.At baseline: mean proteinuria was not significantlychanged over the course of the three urinary collections (88 7.2 mg/h in the morning of 80 10.5 mg/h in the afternoon and 81 10.1 mg/hr during the night). After Ramipril 2.5 mg/day

2015 Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

3. Symptoms of peripheral arterial disease: ramipril

Symptoms of peripheral arterial disease: ramipril Symptoms of peripher Symptoms of peripheral arterial disease: r al arterial disease: ramipril amipril Evidence summary Published: 30 June 2015 nice.org.uk/guidance/esuom45 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in June 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information (...) . Summary The evidence for the efficacy of ramipril in relieving the symptoms of peripheral arterial disease is very limited. Two small RCTs (Ahimastos et al. 2006, n=40 and Shahin et al. 2013a, n=33) found that, compared with placebo, over 24 weeks, ramipril 10 mg daily improved maximum and pain-free walking times and distances in people with stable intermittent claudication, a symptom of peripheral arterial disease. However, while these differences were statistically significant, the clinical

2015 National Institute for Health and Clinical Excellence - Advice

4. Ramipril for claudication?

Ramipril for claudication? Ramipril for claudication? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Ramipril for claudication? View/ Open Date 2013-10 Format Metadata Abstract This ACE inhibitor can help patients with peripheral artery disease walk longer while remaining pain free. URI Part of Citation Journal

2014 PURLS

5. Randomised controlled trial: Ramipril improves walking times and quality of life in patients with stable intermittent claudication

Randomised controlled trial: Ramipril improves walking times and quality of life in patients with stable intermittent claudication Ramipril improves walking times and quality of life in patients with stable intermittent claudication | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ramipril improves walking times and quality of life in patients with stable intermittent claudication Article Text Therapeutics Randomised controlled

2014 Evidence-Based Medicine (Requires free registration)

6. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. (PubMed)

Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Approximately one-third of patients with peripheral artery disease experience intermittent claudication, with consequent loss of quality of life.To determine the efficacy of ramipril for improving walking ability, patient-perceived walking performance, and quality of life in patients with claudication.Randomized, double-blind (...) , placebo-controlled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] years), initiated in May 2008 and completed in August 2011 and conducted at 3 hospitals in Australia.Patients were randomized to receive 10 mg/d of ramipril (n = 106) or matching placebo (n = 106) for 24 weeks.Maximum and pain-free walking times were recorded during a standard treadmill test. The Walking Impairment Questionnaire (WIQ) and Short-Form 36 Health Survey (SF-36) were used

Full Text available with Trip Pro

2013 JAMA

7. Ramipril 2.5 mg/5 ml oral solution

Ramipril 2.5 mg/5 ml oral solution Ramipril 2.5 mg/5 ml oral solution Ramipril 2.5 mg/5 ml oral solution All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Ramipril 2.5 mg/5 ml oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All (...) Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2612. 2012 Authors' conclusions Ramipril oral solution is recommended as an option for use within NHS Wales for: - Treatment of hypertension. - Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease); - diabetes with at least one cardiovascular

2012 Health Technology Assessment (HTA) Database.

8. Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal (PubMed)

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test (...) . Glycemic status was analyzed for the trial plus washout period and for the washout period alone.Following median (interquartile range) 71 (63-86) days drug withdrawal, overall glycemic status remained modestly improved in those allocated ramipril during the trial with an 11% increase in regression to normoglycemia, compared with placebo. In those previously allocated rosiglitazone, glycemic status remained substantially improved with a 49% reduction of new-onset diabetes or death and a 22% increase

Full Text available with Trip Pro

2011 EvidenceUpdates

9. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study

The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study Lamy A, Wang X, Gao P, Tong W, Gafni A, Dans A, Avezum A, Ferreira R, Young J, Yusuf S, Teo K, ONTARGET Investigators Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to compare the costs for the angiotensin-receptor blocker (ARB), telmisartan, and the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in patients with vascular disease or high

2011 NHS Economic Evaluation Database.

10. A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes

A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A combination of telmisartan and ramipril increased renal outcomes in vascular disease or diabetes Article Text Therapeutics A combination of telmisartan and ramipril increased renal

2009 Evidence-Based Medicine (Requires free registration)

11. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. (PubMed)

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor (...) ), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage.The trial ran from 2001 to 2007. After a 3-week run-in period, 25 620 participants were randomly assigned to ramipril 10 mg a day (n=8576), telmisartan 80 mg a day (n=8542), or to a combination of both drugs (n=8502; median follow-up was 56 months), and renal function and proteinuria were measured. The primary renal outcome was a composite

2008 Lancet

12. Telmisartan, ramipril, or both in patients at high risk for vascular events. (PubMed)

Telmisartan, ramipril, or both in patients at high risk for vascular events. In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk (...) diabetes.After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy). The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure.Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction

Full Text available with Trip Pro

2008 NEJM

13. Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure

Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failure Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failureCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Enalapril and captopril increased mortality compared with ramipril in elderly patients with heart failureCommentary Article Text Causation Enalapril and captopril increased

2008 Evidence-Based Nursing

14. Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes

Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes Article Text

2008 Evidence-Based Medicine (Requires free registration)

15. Ramipril/hydrochlorothiazide - Hypertension

Ramipril/hydrochlorothiazide - Hypertension Common Drug Review CEDAC Meeting – May 16, 2007 Page 1 of 2 Notice of Final CEDAC Recommendation – June 14, 2007 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION RAMIPRIL/HYDROCHLOROTHIAZIDE (Altace ® HCT Resubmission – Sanofi-Aventis Canada Inc.) Description: Altace ® HCT is a fixed dose combination of ramipril and hydrochlorothiazide. It is approved for the treatment of essential hypertension in patients for whom this combination therapy (...) is appropriate. Altace ® HCT is not indicated for initial therapy and patients should be titrated to a stable dose of the individual components prior to initiation of therapy with Altace ® HCT. Dosage Forms: Tablets containing ramipril/hydrochlorothiazide in the following ratio: 2.5 mg/12.5 mg, 5 mg/12.5 mg, 5 mg/25 mg, 10 mg/12.5 mg, 10 mg/25 mg. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Altace ® HCT be listed. Reasons for the Recommendation: 1. Altace ® HCT costs

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

16. Ramipril/felodipine extended release

Ramipril/felodipine extended release Common Drug Review CEDAC Meeting – October 18, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – November 15, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION RAMIPRIL/FELODIPINE (Altace ® Plus Felodipine – Sanofi-Aventis Canada Inc.) Description: Altace ® Plus Felodipine is a fixed dose combination of ramipril and an extended release formulation of felodipine. It is approved for the treatment of mild to moderate essential hypertension (...) in patients for whom combination therapy is appropriate. Altace ® Plus Felodipine is not indicated for initial therapy and patients should be titrated to a stable dose of the individual components prior to initiation of therapy with Altace ® Plus Felodipine. Dosage Forms: Tablets containing rampril 2.5 mg/extended release felodipine 2.5 mg and ramipril 5 mg/extended release felodipine 5 mg Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Altace ® Plus Felodipine

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

17. Effect of ramipril on the incidence of diabetes. (PubMed)

Effect of ramipril on the incidence of diabetes. Previous studies have suggested that blockade of the renin-angiotensin system may prevent diabetes in people with cardiovascular disease or hypertension.In a double-blind, randomized clinical trial with a 2-by-2 factorial design, we randomly assigned 5269 participants without cardiovascular disease but with impaired fasting glucose levels (after an 8-hour fast) or impaired glucose tolerance to receive ramipril (up to 15 mg per day) or placebo (...) (and rosiglitazone or placebo) and followed them for a median of 3 years. We studied the effects of ramipril on the development of diabetes or death, whichever came first (the primary outcome), and on secondary outcomes, including regression to normoglycemia.The incidence of the primary outcome did not differ significantly between the ramipril group (18.1%) and the placebo group (19.5%; hazard ratio for the ramipril group, 0.91; 95% confidence interval [CI], 0.81 to 1.03; P=0.15). Participants receiving ramipril

2006 NEJM

18. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). (PubMed)

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). To investigate whether a low dose of the angiotensin converting enzyme (ACE) inhibitor ramipril lowers cardiovascular and renal events in patients with type 2 diabetes who have microalbuminuria or proteinuria.Randomised, double blind, parallel group trial comparing ramipril (1.25 mg (...) was the combined incidence of cardiovascular death, non-fatal myocardial infarction, stroke, heart failure leading to hospital admission, and end stage renal failure.Participants were followed for 3 to 6 (median 4) years. There were 362 primary events among the 2443 participants taking ramipril (37.8 per 1000 patient years) and 377 events among the 2469 participants taking placebo (38.8 per 1000 patient years; hazard ratio 1.03 (95% confidence interval 0.89 to 1.20, P = 0.65)). None of the components

Full Text available with Trip Pro

2004 BMJ

19. Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective

Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective Cost effectiveness of ramipril in patients at high risk for cardiovascular events: economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the statutory health insurance perspective Cost effectiveness of ramipril in patients at high risk (...) drawn. Health technology The use of oral ramipril, given at 10 mg/day, for the treatment of patients with cardiovascular disease (CVD). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients at high risk of cardiovascular events, who had the same characteristics as the patients included in the HOPE study. The HOPE inclusion criteria specified age 55 years or older and high risk

2004 NHS Economic Evaluation Database.

20. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study

Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study Smith M G, Neville A M, Middleton J C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The addition of ramipril (10 mg/day) to standard therapy, for the prevention of cardiovascular events in an at-risk population, was examined. Standard therapy included aspirin, cholesterol-lowering agents, beta-blockers, diuretics, calcium-channel blockers and oral hypoglycaemic agents. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

2003 NHS Economic Evaluation Database.